Sleep Quality and Associated Risk Factors in Leukemia Patients Undergoing Chemotherapy in Iran

Abstract

This study aimed to determine sleep disorders and associated risk factors in leukemia patients undergoing chemotherapy in Imam Khomeini Hospital of Sari, Iran. This cross-sectional study was conducted in 2015 with 100 patients selected. Inclusion criteria included complete mental and psychological health and being over 18 years old, and exclusion criteria included suffering other cancers, other chronic diseases, concurrent radiotherapy, and chemotherapy. The Pittsburgh Sleep Quality standard questionnaire was used to collect data. The questionnaire consisted of mental sleep quality, sleep latency, sleep duration, sleep quality, sleep disturbances, use of sleeping drugs, and impaired daily functioning. Data were analyzed by software SPSS 18 and by using descriptive and inferential tests (Pearson, Spearman, T-test and chi-square). Totals of 47 men (47%) and 53 women (53%) with a mean age of 44.1±1.7, participated in the study. The mean overall score of sleep quality was 9.3±3.9, which represents the average sleep quality in most participants. T-test shows that males have better sleep quality than females (t=2.1; 95%CI:0.004-0.25; P<0.01). Also the sleep quality increased with age (r=0.22, P=0.03). Results show that the amount of sleep quality was only moderate in most patients, so it is necessary to take coping strategies to improve their quality of sleep.

Sleep problems and their interaction with physical activity and fatigue in hematological cancer patients during onset of high dose chemotherapy

“…Based on the cut-off levels of the PSQI, and compared to healthy sample norms [24], our results reveal that sleep problems affected a considerable proportion (ca 75%) of the study population. These findings are in line with those of previous studies that report sleep problems in comparable populations, although these studies mainly focus on later stages of the disease and its treatment (e.g., during or after medical treatment) [4,34]. In contrast, the present study results highlight that sleep problems may occur at the onset, and, more precisely, during the first two weeks of medical therapy.…”

Sleep problems and their interaction with physical activity and fatigue in hematological cancer patients during onset of high dose chemotherapy

“…Based on the cut-off levels of the PSQI, and compared to healthy sample norms [21], our results reveal that sleep problems affected a considerable proportion (ca 75%) of the study population. These ndings are in line with those of previous studies that report sleep problems in comparable populations, although these studies mainly focus on later stages of the disease and its treatment (e.g., during or after medical treatment) [4,31]. In contrast, the present study results highlight that sleep problems may occur at the onset, and, more precisely, during the rst two weeks of medical therapy.…”

Prevalence of Sleep Disturbance in Patients With Cancer: A Systematic Review and Meta-Analysis

“…There was no association between mean age and overall sleep disturbance prevalence rate. Thirty-nine studies involved in this pooled analysis found a significant association between age and sleep disturbance prevalence (Al Maqbali et al, 2021; Bagheri-Nesami et al, 2016; Bardwell et al, 2008; Barsevick et al, 2010; Beck et al, 2010; Berger et al, 2019a; Caplette-Gingras et al, 2013; Chung et al, 2017; Colagiuri et al, 2011; Davies et al, 2017; Desai et al, 2013; Dirksen et al, 2009; Echchikhi et al, 2017; Fekih-Romdhane et al, 2020; Fleming et al, 2019; Grutsch et al, 2011; Halle et al, 2017; Klyushnenkova et al, 2015; Liou et al, 2019; Li et al, 2017a; Liu et al, 2012; Mansano-Schlosser & Ceolim, 2012; Mercadante et al, 2015; Miaskowski et al, 2011; Morris et al, 2015; Palesh et al, 2007, 2008, 2010; Rogers et al, 2008; Santoso et al, 2021; Savard et al, 2005a; Steel et al, 2018; Strollo et al, 2020; Sun et al, 2020; Taylor et al, 2012; Tejada et al, 2019; Yoshikawa et al, 2020; Zubair et al, 2019). This was because there are differences in sleep disturbance prevalence depending on the stage of treatment.…”